Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 14/20 | 0.42 |
| ▸ | CTSS | P25774 | 9/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23990006 | 0.85 | CA1 (0.42) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL28976538 | 0.85 | CA1 (0.42) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL1994817 | 0.83 | ACACB (0.30) | — | |
| SCHEMBL1994818 | 0.83 | ACACB (0.30) | — | |
| SCHEMBL2405498 | 0.82 | CA1 (0.46) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL3212391 | 0.82 | CA1 (0.46) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL5450014 | 0.82 | CTSK (0.50) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL5045442 | 0.81 | CA1 (0.45) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL2402020 | 0.81 | CA1 (0.45) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL10829328 | 0.81 | CTSK (0.46) | CA1CA2CA7CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067999-A1 | Carbazole derivatives and their use as neuropeptide y5 receptor ligands | ASTRAZENECA AB (SE) | 2004-04-08 | — | — | US | disclosed |
| EP-1358157-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002051806-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067999-A1 | Carbazole derivatives and their use as neuropeptide y5 receptor ligands | NPY5R, NPY1R, NPY2R | CA1 1263/4885CA2 1117/4885CA7 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.